Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma-Reference-Cited by-同舟云学术

Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma

Published:2020-11-11 Issue:1 Volume:20 Page:132-141
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Martín-Broto Javier^ORCID,Pousa Antonio López,Brohl Andrew S.,Van Tine Brian A.^ORCID,Powers Benjamin^ORCID,Stacchiotti Silvia,Blay Jean-Yves^ORCID,Hu James S.,Oakley Gerard J.,Wang Hong,Szpurka Anna M.,Levy Donna E.,Mo Gary,Ceccarelli Matteo,Jones Robin L.^ORCID

Funder

Antonia Baldo of Syneos Health

Eli Lilly and Company

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional and clinical roles of stromal PDGF receptors in tumor biology;Cancer and Metastasis Reviews;2024-07-09

2. Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas;Scientific Reports;2024-05-29

3. Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care;Seminars in Radiation Oncology;2024-04

4. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma;Clinical Cancer Research;2023-06-29

5. Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study;Cancer Communications;2023-02-03